{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T18:24:02Z","timestamp":1770315842150,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Exploratory Research Project of Zhongshan Hospital, Qingpu Branch","award":["No. QYT2023-01"],"award-info":[{"award-number":["No. QYT2023-01"]}]},{"name":"the National Natural Science Foundation of China Youth Fund Project","award":["No. 82300146"],"award-info":[{"award-number":["No. 82300146"]}]},{"name":"the Clinical Research Innovation Plan of Shanghai General Hospital","award":["No. CCTR-2025C49"],"award-info":[{"award-number":["No. CCTR-2025C49"]}]},{"name":"the Clinical Research Innovation Plan of Shanghai General Hospital","award":["No. CCTR-2022B01"],"award-info":[{"award-number":["No. CCTR-2022B01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06809-4","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:25:23Z","timestamp":1768281923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic portal hypertension following inotuzumab ozogamicin in a low-risk patient: a case of overriding baseline risk and long-term management"],"prefix":"10.1007","volume":"105","author":[{"given":"Jinchun","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianmin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"8","key":"6809_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.clml.2020.03.004","volume":"20","author":"T Badar","year":"2020","unstructured":"Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E (2020) Real-World outcomes of adult B-Cell acute lymphocytic leukemia patients treated with inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk 20(8):556\u2013560e552. https:\/\/doi.org\/10.1016\/j.clml.2020.03.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"6809_CR2","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/ejh.14405","volume":"114","author":"A Bruzzese","year":"2025","unstructured":"Bruzzese A, Martino EA, Labanca C, Carid\u00e0 G, Mendicino F, Lucia E, Olivito V, Puccio N, Neri A, Morabito F, Vigna E, Gentile M (2025) Therapeutic strategies for relapsed or refractory B-Cell acute lymphoblastic leukemia in adult patients: optimizing the use of monoclonal antibodies. Eur J Haematol 114(6):938\u2013952. https:\/\/doi.org\/10.1111\/ejh.14405","journal-title":"Eur J Haematol"},{"issue":"5","key":"6809_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3324\/haematol.2023.284310","volume":"109","author":"S Kayser","year":"2024","unstructured":"Kayser S, Sartor C, Giglio F, Bruno A, Webster J, Chiusolo P, Saraceni F, Guerzoni S, Pochintesta L, Borlenghi E, Marconi G, Zacheo I, Cerrano M, Salutari P, Restuccia F, Abbenante M, Levis MJ, Schlenk RF, Papayannidis C (2024) Impact of inotuzumab Ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome\/venous occlusive disease. Haematologica 109(5):1385\u20131392. https:\/\/doi.org\/10.3324\/haematol.2023.284310","journal-title":"Haematologica"},{"issue":"5","key":"6809_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/ajh.27637","volume":"100","author":"M de Lima","year":"2025","unstructured":"de Lima M, Kebriaei P, Lanza F, Cho C, Popradi G, Kaur M, Zhang MJ, Zhang F, Shah R, Vandendries E, Asomaning K, Dorman S, Stelljes M, Marks DI, Saber W (2025) Five-Year Real\u2010World safety of inotuzumab Ozogamicin before hematopoietic stem cell transplantation in B\u2010Cell precursor acute lymphoblastic leukemia. Am J Hematol 100(5):909\u2013912. https:\/\/doi.org\/10.1002\/ajh.27637","journal-title":"Am J Hematol"},{"key":"6809_CR5","doi-asserted-by":"publisher","first-page":"933317","DOI":"10.3389\/fonc.2022.933317","volume":"12","author":"F Giglio","year":"2022","unstructured":"Giglio F, Xue E, Greco R, Lazzari L, Clerici DT, Lorentino F, Mastaglio S, Marktel S, Lupo-Stanghellini MT, Marcatti M, Corti C, Bernardi M, Piemontese S, Ciceri F, Peccatori J (2022) Defibrotide prophylaxis of sinusoidal obstruction syndrome in adults treated with inotuzumab Ozogamicin prior to hematopoietic stem cell transplantation. Front Oncol 12:933317. https:\/\/doi.org\/10.3389\/fonc.2022.933317","journal-title":"Front Oncol"},{"issue":"8","key":"6809_CR6","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/s2352-3026(17)30103-5","volume":"4","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O\u2019Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI (2017) Hepatic adverse event profile of inotuzumab Ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol 4(8):e387\u2013e398. https:\/\/doi.org\/10.1016\/s2352-3026(17)30103-5","journal-title":"Lancet Haematol"},{"issue":"6","key":"6809_CR7","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1097\/js9.0000000000002435","volume":"111","author":"X Duan","year":"2025","unstructured":"Duan X, Deng Y, Li L, Yin Z, Yu L (2025) Safety evaluation of inotuzumab ozogamicin: a pharmacovigilance study based on the FAERS database. Int J Surg 111(6):4094\u20134102. https:\/\/doi.org\/10.1097\/js9.0000000000002435","journal-title":"Int J Surg"},{"issue":"1","key":"6809_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12185-021-03217-4","volume":"115","author":"A Izumi","year":"2021","unstructured":"Izumi A, Tachibana T, Ando T, Tanaka M, Kanamori H, Nakajima H (2021) A case series of patients treated with inotuzumab Ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation. Int J Hematol 115(1):69\u201376. https:\/\/doi.org\/10.1007\/s12185-021-03217-4","journal-title":"Int J Hematol"},{"issue":"3","key":"6809_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00277-025-06305-1","volume":"104","author":"Y Jia","year":"2025","unstructured":"Jia Y, Xia X, Yang J, Cai Y, Tong Y, Qiu H, Huang C, Zhou K, Zhang Y, Shen C, Wan L, Song X (2025) Improved survival in older patients with myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with low-dose anti-thymocyte globin (ATG)\/post-cyclophosphamide (PTCy)-based regimen for graft-versus-host disease prophylaxis. Ann Hematol 104(3):1857\u20131866. https:\/\/doi.org\/10.1007\/s00277-025-06305-1","journal-title":"Ann Hematol"},{"issue":"10","key":"6809_CR10","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.bbmt.2018.06.013","volume":"24","author":"C Strouse","year":"2018","unstructured":"Strouse C, Zhang Y, Zhang M-J, DiGilio A, Pasquini M, Horowitz MM, Lee S, Ho V, Ramanathan M, Chinratanalab W, Loren A, Burns LJ, Artz A, Villa KF, Saber W (2018) Risk score for the development of Veno-Occlusive disease after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant 24(10):2072\u20132080. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.013","journal-title":"Biol Blood Marrow Transplant"},{"key":"6809_CR11","doi-asserted-by":"publisher","unstructured":"Lee J, Yoon J-H, Kwag D, Lee J-H, Kim TY, Min GJ, Park S-S, Park S, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, Kim H-J, Min C-K, Cho S-G, Wook Lee J, Hak Lee S, Lee S (2021) Hepatic venoocclusive disease\/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab Ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy. Therapeutic Adv Hematol 12. https:\/\/doi.org\/10.1177\/20406207211066176","DOI":"10.1177\/20406207211066176"},{"issue":"1","key":"6809_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s44313-025-00077-3","volume":"60","author":"K-H Sung","year":"2025","unstructured":"Sung K-H, Kwag D, Min GJ, Park S-S, Park S, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, Kim H-J, Min C-K, Cho S-G, Lee S, Yoon J-H (2025) Atypical features of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after inotuzumab Ozogamicin in adult patients with acute lymphoblastic leukemia. Blood Res 60(1):28. https:\/\/doi.org\/10.1007\/s44313-025-00077-3","journal-title":"Blood Res"},{"issue":"3","key":"6809_CR13","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/cam4.4390","volume":"11","author":"F Ravaioli","year":"2022","unstructured":"Ravaioli F, Marconi G, Martinelli G, Dajti E, Sartor C, Abbenante MC, Alemanni LV, Nanni J, Rossini B, Parisi S, Colecchia L, Cristiano G, Marasco G, Vestito A, Paolini S, Bonifazi F, Curti A, Festi D, Cavo M, Colecchia A, Papayannidis C (2022) Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab Ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. Cancer Med 11(3):618\u2013629. https:\/\/doi.org\/10.1002\/cam4.4390","journal-title":"Cancer Med"},{"key":"6809_CR14","doi-asserted-by":"publisher","unstructured":"Mavrikou I, Chatzidimitriou D, Skoura L, Nikolousis E, Sakellari I, Gavriilaki E (2023) Molecular advances in sinusoidal obstruction Syndrome\/Veno-Occlusive disease. Int J Mol Sci 24(6). https:\/\/doi.org\/10.3390\/ijms24065620","DOI":"10.3390\/ijms24065620"},{"issue":"21","key":"6809_CR15","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1002\/cncr.35505","volume":"130","author":"HM Kantarjian","year":"2024","unstructured":"Kantarjian HM, Boissel N, Papayannidis C, Luskin MR, Stelljes M, Advani AS, Jabbour EJ, Ribera JM, Marks DI (2024) Inotuzumab Ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions. Cancer 130(21):3631\u20133646. https:\/\/doi.org\/10.1002\/cncr.35505","journal-title":"Cancer"},{"issue":"2","key":"6809_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00277-023-05495-w","volume":"103","author":"D Fischer","year":"2024","unstructured":"Fischer D, Toenges R, Kiil K, Michalik S, Thalhammer A, Bug G, G\u00f6kbuget N, Lang F (2024) Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome\u2013negative acute lymphoblastic leukemia. Ann Hematol 103(2):489\u2013498. https:\/\/doi.org\/10.1007\/s00277-023-05495-w","journal-title":"Ann Hematol"},{"issue":"1","key":"6809_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/17474086.2025.2450223","volume":"18","author":"DI Marks","year":"2025","unstructured":"Marks DI, Cassaday RD, Ribera J-M, Schuh AC, Park JH, Chiaretti S, Stelljes M (2025) Characterizing the ideal patient for treatment with inotuzumab Ozogamicin for relapsed\/refractory acute lymphoblastic leukemia: a systematic literature review. Expert Rev Hematol 18(1):91\u2013103. https:\/\/doi.org\/10.1080\/17474086.2025.2450223","journal-title":"Expert Rev Hematol"},{"issue":"9823","key":"6809_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, Boelens JJ, Hewitt A, Schrum J, Schulz AS, M\u00fcller I, Stein J, Wynn R, Greil J, Sykora K-W, Matthes-Martin S, F\u00fchrer M, O\u2019Meara A, Toporski J, Sedlacek P, Schlegel PG, Ehlert K, Fasth A, Winiarski J, Arvidson J, Mauz-K\u00f6rholz C, Ozsahin H, Schrauder A, Bader P, Massaro J, D\u2019Agostino R, Hoyle M, Iacobelli M, Debatin K-M, Peters C, Dini G (2012) Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric Haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 379(9823):1301\u20131309. https:\/\/doi.org\/10.1016\/s0140-6736(11)61938-7","journal-title":"Lancet"},{"key":"6809_CR19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286091","author":"M \u00d6zcan","year":"2025","unstructured":"\u00d6zcan M, Cassaday RD, Zarzycka E, Vandendries E, Zhang F, Chen Y, Nieto A, Demirkan F, Montesinos P, Altuntas F (2025) Efficacy and safety of currently approved and lower starting doses of inotuzumab Ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2024.286091","journal-title":"Haematologica"},{"issue":"5","key":"6809_CR20","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/ajh.27254","volume":"99","author":"IF Khouri","year":"2024","unstructured":"Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ (2024) Safety and long-term survival results of the addition of inotuzumab Ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single\u2010center phase 1,2 trial. Am J Hematol 99(5):836\u2013843. https:\/\/doi.org\/10.1002\/ajh.27254","journal-title":"Am J Hematol"},{"key":"6809_CR21","doi-asserted-by":"publisher","unstructured":"Kareem R, Nadeem A, Us Sehar N, Majid Z, Fatima T, Anwar R (2025) Should transjugular intrahepatic portosystemic shunt be first-line therapy for preventing esophageal variceal rebleeding? A meta-analysis of clinical outcomes. Baylor Univ Med Center Proc 38 (5):627\u2013636. https:\/\/doi.org\/10.1080\/08998280.2025.2514978","DOI":"10.1080\/08998280.2025.2514978"},{"issue":"6","key":"6809_CR22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/10428194.2025.2449582","volume":"66","author":"J Senapati","year":"2025","unstructured":"Senapati J, Kantarjian H, Habib D, Haddad FG, Jain N, Short NJ, Jabbour E (2025) Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and Harnessing efficacy. Leuk Lymphoma 66(6):989\u20131000. https:\/\/doi.org\/10.1080\/10428194.2025.2449582","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"6809_CR23","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1080\/10428194.2024.2364043","volume":"65","author":"NJ Short","year":"2024","unstructured":"Short NJ, Kantarjian H, Jabbour E (2024) Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens. Leuk Lymphoma 65(10):1405\u20131417. https:\/\/doi.org\/10.1080\/10428194.2024.2364043","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6809_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood.2024023930","volume":"144","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Short NJ, Kantarjian HM, Chang T-C, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips AH, Khoury J, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris RS, Nasr LF, Kriwacki RW, Roberts KG, Konopleva M, Jabbour EJ, Mullighan CG (2024) Genomic determinants of response and resistance to inotuzumab Ozogamicin in B-cell ALL. Blood 144(1):61\u201373. https:\/\/doi.org\/10.1182\/blood.2024023930","journal-title":"Blood"},{"issue":"12","key":"6809_CR25","doi-asserted-by":"publisher","first-page":"e8289","DOI":"10.1002\/ccr3.8289","volume":"11","author":"SM Huang","year":"2023","unstructured":"Huang SM, Wan CL, Cao HY, Li YY, Qian CS, Zhou HX, Xu MZ, Hu XH, Dai L, Dai HP, Xue SL (2023) Preemptive inotuzumab Ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy. Clin Case Rep 11(12):e8289. https:\/\/doi.org\/10.1002\/ccr3.8289","journal-title":"Clin Case Rep"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06809-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06809-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06809-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T03:33:08Z","timestamp":1770262388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06809-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6809"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06809-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report and literature review were conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments. Ethical approval for the retrospective analysis and publication of anonymized clinical data was granted by Shanghai General Hospital Ethics Committee (Approval Number: 2025\u2009\u2212\u2009434). Written informed consent for the publication of anonymized medical information was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}